B

Blueprint Medicines Corp
D

BPMC

96.820
USD
0.23
(0.24%)
Market Open
Volume
8,221
EPS
-4
Div Yield
-
P/E
-46
Market Cap
6,163,276,803
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    177.24 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.75 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    154.55 USD
    LLY
    LLY
    -40.34
    (-5.13%)
    745.63 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    100.1 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.575 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.6 USD
    More
News

Title: Blueprint Medicines Corp

Sector: Healthcare
Industry: Biotechnology
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.